● Recruiting

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Condition: Retinopathy of Prematurity (ROP) · Sponsor: Wang Yusheng

PhaseNA

Planned participants146

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)

This description comes directly from the study's public registry record.

Talk to the study team

Wang · 02984771794 · wangys003@126.com

Always discuss trial participation with your own doctor first.

Locations (3)

Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University	Xi'an, Shaanxi, China	Recruiting
Department of Ophthalmology, Xijing Hospital, Air Force Military Medical University	Xi'an, Shaanxi, China	Recruiting
Department of Ophthalmology, Xianyang Rainbow Hospital	Xianyang, Shaanxi, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06717412